Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Daniel A. King

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6451-712X; OpenAlex author ID A5059834620. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 1, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 4 papers, 1 trial · 2024: 6 papers · 2025: 6 papers · 2026: 7 papers

Papers 27

  1. Medicaid Expansion Timing and Pancreatic Cancer Resection Rates and Survival. Co-author DOI 10.1001/jamasurg.2026.0057↗
  2. Computationally assisted patient finding for navigation to optimize pancreatic cancer care access. Co-author DOI 10.1093/oncolo/oyag037↗
  3. Implantable Microdevices for In Vivo Assessment of Chemotherapy Response in Patient Derived Organoid Orthotopic Pancreatic Cancer Models. Co-author DOI 10.1097/sla.0000000000007071↗
  4. From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer. First author DOI 10.21037/jgo-2026-1-0153↗
  5. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  6. Presentation, Treatment, and Outcomes of Non-bacterial Thrombotic Endocarditis in Pancreatic Cancer: A Systematic Review. Last author DOI 10.7759/cureus.104500↗
  7. Carboplatin May Be an Effective and Tolerable Treatment Option for Platinum-Sensitive Pancreatic Cancer Patients With Pre-existing Neuropathy. Last author DOI 10.7759/cureus.110034↗
  8. Evaluating the Association of Area Deprivation Index (ADI) on Postoperative Outcomes in Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27996↗
  9. Impact of Environmental Quality on Pancreatic Cancer Outcomes Post Pancreatoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-025-01254-4↗
  10. GATA6 Amplification Is Associated With Improved Survival in TP53-Mutated Unresectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000002431↗
  11. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  12. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  13. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32020103↗
  14. Machine learning to predict completion of treatment for pancreatic cancer. Co-author DOI 10.1002/jso.27812↗
  15. Outcomes of minimally invasive vs. open pancreatoduodenectomies in pancreatic adenocarcinoma: analysis of ACS-NSQIP data. Co-author DOI 10.1007/s00423-024-03454-1↗
  16. Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. Co-author DOI 10.1007/s00423-024-03483-w↗
  17. Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. Co-author DOI 10.1007/s12029-024-01119-2↗
  18. Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting. Co-author DOI 10.1245/s10434-024-15352-3↗
  19. ASO Author Reflections: Identifying and Understanding How Vulnerable Populations Are Affected by Delays in Pancreatic Cancer Care. Co-author DOI 10.1245/s10434-024-15476-6↗
  20. Socioeconomic and Demographic Barriers Associated with Delays in Pancreatic Cancer Germline Genetic Testing Last author DOI 10.1101/2023.07.17.23292736↗
  21. Development of a Neoadjuvant Treatment Pathway to Standardize Pancreatic Cancer Care and Improve Outcomes Across a Large Diverse Health System Last author DOI 10.1101/2023.09.19.23295749↗
  22. Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens. Co-author DOI 10.1172/jci.insight.172449↗
  23. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therap… Co-author DOI 10.1200/po.21.00489↗
  24. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000005558↗
  25. Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer. Co-author DOI 10.7150/thno.73218↗
  26. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and o… Co-author DOI 10.1101/2021.12.16.21267326↗
  27. Marked Decrease in CA 19-9 Level Belies Rapidly Progressive Lymphangitic Carcinomatosis in a Case of Metastatic Pancreatic Cancer. Co-author DOI 10.1089/pancan.2020.0015↗

Trials 1

  1. Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy Principal investigator NCT07122466↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Danielle K. DePeralta · 10 shared papers, 2022–2026 · strength 2.15
  2. Oliver J. Standring · 10 shared papers, 2022–2026 · strength 2.11
  3. Sepideh Gholami · 8 shared papers, 2024–2026 · strength 1.90
  4. Lyudmyla Demyan · 9 shared papers, 2022–2026 · strength 1.78
  5. Shamsher Ali Pasha · 9 shared papers, 2022–2025 · strength 1.75
  6. David Arthur Tuveson · 8 shared papers, 2022–2026 · strength 1.49
  7. Marcovalerio Melis · 6 shared papers, 2024–2025 · strength 1.33
  8. Matthew John Weiss · 6 shared papers, 2024–2025 · strength 1.33
  9. Elliot Newman · 6 shared papers, 2024–2025 · strength 1.33
  10. Abdullah Khalid · 6 shared papers, 2024–2025 · strength 1.33
  11. Matthew John Weiss · 6 shared papers, 2022–2025 · strength 1.02
  12. Joseph M. Herman · 6 shared papers, 2021–2024 · strength 0.85
  13. Benjamin Marc Ascherman · 1 shared paper, 2026 · strength 0.63
  14. Craig Devoe · 3 shared papers, 2025 · strength 0.56
  15. Julien T. Hohenleitner · 2 shared papers, 2026 · strength 0.54
  16. Eileen Mary O'Reilly · 3 shared papers, 2025–2026 · strength 0.53
  17. Robert C. Grant · 3 shared papers, 2025–2026 · strength 0.53
  18. Grainne Mary O'Kane · 3 shared papers, 2025–2026 · strength 0.53
  19. Andrew J. Aguirre · 3 shared papers, 2025–2026 · strength 0.53
  20. Jennifer Jane Knox · 3 shared papers, 2025–2026 · strength 0.53
  21. Elizabeth M. Jaffee · 3 shared papers, 2025–2026 · strength 0.53
  22. Brian Matthew Wolpin · 3 shared papers, 2025–2026 · strength 0.53
  23. Steve Gallinger · 3 shared papers, 2025–2026 · strength 0.53
  24. Erica S. Tsang · 3 shared papers, 2025–2026 · strength 0.53
  25. Kimberly J. Perez · 3 shared papers, 2025–2026 · strength 0.53

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.